SCHEMBL321149

SCHEMBL321149

CC1(O)C[N]C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1040352 0.77
SCHEMBL241146 0.73
SCHEMBL3941998 0.73
SCHEMBL6074609 0.70
SCHEMBL69189 0.67
SCHEMBL739757 0.67
SCHEMBL1856892 0.67
SCHEMBL10391546 0.64
SCHEMBL10391595 0.64
SCHEMBL1547226 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113348165-B 1,2, 4-Triazin-3 (2H) -one compounds for the treatment of hyperproliferative diseases 拜耳股份有限公司 2024-06-25 CN claimed
WO-2024118887-A1 N-PHENYL-PYRAZOLO[1,5-A]PYRIDINE-3-CARBOXAMIDE DERIVATIVES AS WILD TYPE C-KIT KINASE INHIBITORS FOR THE TREATMENT OF URTICARIA BLUEPRINT MEDICINES CORPORATION (US) 2024-06-06 WO claimed
CN-118019736-A Molecular gel compound designed based on cereblon protein and application thereof 标新生物医药科技(上海)有限公司 2024-05-10 CN claimed
US-20240124474-A1 HER2 MUTATION INHIBITORS ARRAY BIOPHARMA INC. (US) 2024-04-18 US claimed
WO-2024051766-A1 MOLECULAR GLUE COMPOUND BASED ON CEREBLON PROTEIN DESIGN AND USE THEREOF 标新生物医药科技(上海)有限公司 2024-03-14 WO claimed
US-20240043435-A1 TYK-2 INHIBITOR BEONE MEDICINES I GMBH (CH) 2024-02-08 US claimed
WO-2024006897-A1 INDAZOLE COMPOUNDS TYRA BIOSCIENCES, INC. (US) 2024-01-04 WO claimed
EP-4168398-A1 TYK-2 INHIBITOR BeiGene, Ltd. (KY) 2023-04-26 EP claimed
CN-115715288-A TYK-2 inhibitors 百济神州有限公司 2023-02-24 CN claimed
US-20230023851-A1 HER2 MUTATION INHIBITORS ARRAY BIOPHARMA INC. (US) 2023-01-26 US claimed
EP-3148995-A1 6-SUBSTITUTED-3H-1,3-BENZOTHIAZOL-2-ONE COMPOUNDS AS TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONISTS Eli Lilly and Company (US) 2017-04-05 EP claimed
US-9469632-B2 6-substituted-3H-1,3-benzothiazol-2-one compounds as TARP-gamma 8 dependent AMPA receptor antagonists ELI LILLY AND COMPANY (US) 2016-10-18 US claimed
US-20160297833-A1 THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS Bayer Pharma AG (DE) 2016-10-13 US claimed
US-20160279109-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS DR. REDDY'S LABORATORIES LTD. (IN) 2016-09-29 US claimed
US-9394305-B2 Substituted imidazo[1,2-a]pyridine compounds as tropomyosin receptor kinase a (TrkA) inhibitors DR. REDDY'S LABORATORIES LTD. (IN) 2016-07-19 US claimed
US-20150368238-A1 SUBSTITUTED IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TrkA) INHIBITORS DR. REDDY'S LABORATORIES LTD. (IN) 2015-12-24 US claimed
WO-2015183673-A1 6-SUBSTITUTED-3H-1,3-BENZOTHIAZOL-2-ONE COMPOUNDS AS TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2015-12-03 WO claimed
US-20150344468-A1 6-SUBSTITUTED-3H-1,3-BENZOTHIAZOL-2-ONE COMPOUNDS AS TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY 2015-12-03 US claimed
US-8853392-B2 Benzamide mGluR5 positive allosteric modulators and methods of making and using same VANDERBILT UNIVERSITY (US) 2014-10-07 US claimed
WO-2009016410-A2 CHEMICAL COMPOUNDS 831 ASTRAZENECA AB (SE) 2009-02-05 WO claimed